Daridorexant hydrochloride is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Post-Traumatic Stress Disorder (PTSD). According to GlobalData, Phase I drugs for Post-Traumatic Stress Disorder (PTSD) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Daridorexant hydrochloride LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Daridorexant hydrochloride overview
Daridorexant Hydrochloride (Quviviq) is under development for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance and post-traumatic stress disorder (PTSD). The drug candidate is a sleep-inducing agent that is administered through oral route in the form of tablets.
Idorsia Pharmaceutical overview
Idorsia Pharmaceutical (Idorsia) is a biopharmaceutical company that discovers, develops, and commercializes small molecules to treat the central nervous system and cardiovascular and immunological disorders. It is investigating daridorexant against insomnia; aprocitentan for the treatment of resistant hypertension; clazosentan to treat cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage; and L-lucerastat compound targeting fabry disease. The company is also evaluating drugs against suspected acute myocardial infarction, systemic lupus erythematosus, Binge eating disorder and rare lysosomal storage disorders. It works in collaboration with Janssen Biotech to develop and commercialize aprocitentan drug candidates. Idorsia is headquartered in Allschwil, Switzerland.
For a complete picture of Daridorexant hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.